NCT00041808View on ClinicalTrials.gov

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2001

Study Completion Date

April 30, 2003

Conditions

Metastases, NeoplasmColorectal NeoplasmsEsophageal NeoplasmsStomach NeoplasmsPancreatic NeoplasmsBreast NeoplasmsMelanomaSarcomaGastrointestinal NeoplasmsLung NeoplasmsLiver NeoplasmsCholangiocarcinoma

Interventions

DRUG

MTC-DOX for Injection

PROCEDURE

Chemotherapy

Trial Locations (4)

60590

Frankfurt Universtiy, Frankfurt

76508

Scott and White Clinic, Temple

92037

Scripps Stevens Cancer Division, San Diego

94143

UCSF Cancer Center, San Francisco

All Listed Sponsors

lead

FeRx

INDUSTRY

NCT00041808 - Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver | Biotech Hunter | Biotech Hunter